About ConcePTION

ConcePTION is a project funded by the Innovative Medicines Initiative, a private public partnership. The project was launched in April 2019.

We believe that we have an important societal obligation to radically and rapidly reduce uncertainty about the effects of medication used during pregnancy and breastfeeding to benefit women in making informed decisions about medications used before, during and after pregnancy.

Reporting medicine use in pregnancy

Did you use any medicines when you were pregnant? Here is how you and your health care provider can report what we call an exposure.

Ten principles for stakeholder engagement in the ConcePTION project

The ConcePTION project is building much-needed knowledge for women and health care professionals. To achieve our goal of building an ecosystem for medicine safety in pregnancy and breastfeeding, we need to engage with women, their partners, their doctors, pharmacists, midwives and nurses, the companies that develop medicines and the authorities that approve them and decide what becomes available to patients. Our goal is to work in an open and inclusive way, with the spirit of mutual respect and trust. Here is how we engage with stakeholders in an ethical way.


The ConcePTION project is designing and building a lasting ecosystem of data collections, methods, people and infrastructures, that allow generation and dissemination of evidence on medicine safety in pregnancy and lactation. Addressing a knowledge gap for mothers and health care professionals, impacting more than 5 million women across the European Union that get pregnant every year. Join us on 15 February at 15:00 CET to learn how the ConcePTION is bridging this gap in an efficient, systematic and ethically responsible way!  | READ MORE >>
Postpartum depression is surprisingly common, affecting some 10-15% of new mothers. Antidepressants are often prescribed, which raises questions about how safe it is to breastfeed while undergoing medical treatment. This is of course a concern for parents, who want to know if their baby will suffer any adverse effects. But nurses, midwives, pharmacists and doctors rarely have the evidence needed to help women make an informed choice between breast and bottle. An editorial in the Pharmaceutical journal raises this and other questions that parents often do not ask, but where health care professionals could provide both answers and support to parents.  | READ MORE >>
The impact of medicine use in pregnancy is difficult to study. There has been increasing attention to how particular medicines can affect children’s neurodevelopment. The ConcePTION project recently published an inventory of European data sources that can support research on the neurodevelopmental effects of exposure to medicines in pregnancy.  | READ MORE >>


🎉 We're celebrating three years of the #DrugSafetyMatters podcast! 🎉

After 31 episodes and 20 000 downloads later, we can't wait to hear what future editions have in store from the world of #pharmacovigilance.

🎧 Listen now at 👉 http://www.drugsafetymatterspod.org

Large investments have been made in data catalogues to FAIRify data descriptions, But diversity also creates heterogeneity, We have analysed catalogues for human subjects, ranging from cohort studies to surveillance, administrative & healthcare records 👇

The ConcePTION consortium

The project unites an unprecedented 88 organizations from 22 countries, including the European Medicines Agency, drug manufacturers, academia, public health organizations, and teratology networks to innovate new solutions to a decades-long public health issue.


The ConcePTION project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821520. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.